



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No.: 8654/2072

PATENT

TECH. CENTER 1600/2900

MAY 15 2002

RECEIVED

Application of: Krissansen, et al.  
Serial No.: 10/014,887  
Filed: December 11, 2001  
Entitled: "Cancer Therapy"

Examiner:  
Group Art Unit: 1615  
Conf. No.: 2382

**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that the papers attached hereto are being deposited with the United States Postal Service using Express Mail to Addressee service, **Express Mail No. EV097555031US** on this date, May 9, 2002, postage prepaid under 37 C.F.R. Section 1.10 in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231.

David J. Dykeman

Name of Person Mailing Paper

Signature of Person Mailing Paper

**Commissioner for Patents  
Washington, D.C. 20231**

**TRANSMITTAL LETTER**

Enclosed for filing in the above-identified patent application, please find the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449 Citing 10 references;
3. Copies of 10 Cited References;
4. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 58654/2002. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted

Date: May 9, 2002

Name: David J. Dykeman  
Registration No.: 46,678  
Customer No.: 29933  
Palmer & Dodge LLP  
111 Huntington Avenue  
Boston, MA 02199-7613  
Tel: 617-239-0100



Atty. Docket No.: 8654/2072

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Krissansen, et al.  
Serial No.: 10/014,887  
Filed: December 11, 2001  
Entitled: "Cancer Therapy"

Examiner:

Group Art Unit: 1615  
Conf. No.: 2382

TECH CENTER 1600/2900

MAY 15 2002

RECEIVED

**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that the papers attached hereto are being deposited with the United States Postal Service using Express Mail to Addressee service, **Express Mail No. EV097555031US** on this date, May 9, 2002, postage prepaid under 37 C.F.R. Section 1.10 in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231.

David J. Dykeman

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office. A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list.

Pursuant to CFR § 1.97(e)(1), each item contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application or International application. A copy of the PCT International Search Report for Application No. PCT/NZ00/00098 dated 31 October 2000 is included and cited in on the enclosed PTO-1449.

Because this statement is being filed before the mailing of the First Office Action on the merits, no fee is believed to be due. However, should the Office feel otherwise, the Commissioner is hereby authorized to charge any necessary fees to Deposit Account 16-0085, Reference No. 8654/2002.


Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Date: May 9, 2002

Respectfully submitted,

Name: David J. Dykeman  
Registration No.: 46,678  
Customer No.: 29933  
Palmer & Dodge LLP  
111 Huntington Avenue  
Boston, MA 02199-7613  
Tel: 617-239-0100

**RECEIVED**

MAY 15 2002

TECH CENTER 1600/2900

SPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket No. 8654/2072		Serial No. 10/017,887	
INFORMATION DISCLOSURE STATEMENT				Applicant(s): Krissansen, et al.			
				Filing Date: December 11, 2001		Group: 1615	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation
							YES NO
	A.	EP0278176	August 17, 1998	Europe	C07D	311/86	
<b>OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)</b>							
	B.	PCT Internaional Sear Report for Application No. PCT/NZ00/00098 dated 31 October 2000					
	C.	Cao Z. et al. "Thalidomide increases both intra-tumoural tumour necrosis factor- $\alpha$ production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetice acid" <u>British Journal of Cancer</u> (1999) volume 80(5/6), pages 716-723.					
	D.	Fujii H. et al. "Vaccination with B7-18 tumor and anti-adhesion therapy with RGD pseudo-peptide (FC-336) efficiently induce anti-metastatic effect" <u>Clinical &amp; Experimental Metastasis</u> (1998) volume 16, pages 141-148.					
	E.	Pedley R.B. et al. "Ablation of colrectoral xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents" <u>Cancer Research</u> (1996) volume 56, pages 3293-3300.					
	F.	Zitvogel L. "Interleukin-12 and b7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumor" <u>Journal of Immunology</u> (1996) volume 26, pages 1335-13421.					
	G.	Lissoni P. et al. "Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin Preliminary results" <u>European Journal of Cancer</u> (1993) volume 29A(2), pages 185-189.					
	H.	Hornung R.L. et al. "Augmentation of natural killer activity, induction of IFN and development tumor activity during the successful treatment of established tumor murine renal cancer using flavoneacetic acid and IL-2" <u>The Journal of Immunology</u> (1998) volume 141(10), pages 3671-3679					
	I.	Nawrocki S. and Mackiewicz A. "Genetically modified tumour vaccines-where we are today" <u>Cancer Treatment Reviews</u> (1999) volume 25, pages 29-46.					
	J.	Thrash-Bingham C.A. and Tartof K.D. "aHIF: A natural antisense transcript overexpressed in human renal cancer during hypoxia" <u>The Journal of the National Cancer Institute</u> (1999) volume 91(2), pages 143-151					
EXAMINER					DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							
**Copies of references not provided at the time of this submission.							